Search Results - "ESSELTINE, Dixie L"

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma by San Miguel, Jesús F, Schlag, Rudolf, Khuageva, Nuriet K, Dimopoulos, Meletios A, Shpilberg, Ofer, Kropff, Martin, Spicka, Ivan, Petrucci, Maria T, Palumbo, Antonio, Samoilova, Olga S, Dmoszynska, Anna, Abdulkadyrov, Kudrat M, Schots, Rik, Jiang, Bin, Mateos, Maria-Victoria, Anderson, Kenneth C, Esseltine, Dixie L, Liu, Kevin, Cakana, Andrew, van de Velde, Helgi, Richardson, Paul G

“…Patients with newly diagnosed multiple myeloma who were ineligible for treatment with high-dose chemotherapy plus hematopoietic stem-cell transplantation were…”
Get full text

Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial by MATEOS, Maria-Victoria, RICHARDSON, Paul G, SAMOILOVA, Olga S, DMOSZYNSKA, Anna, ABDULKADYROV, Kudrat M, SCHOTS, Rik, BIN JIANG, ESSELTINE, Dixie L, LIU, Kevin, CAKANA, Andrew, VAN DE VELDE, Helgi, SAN MIGUEL, Jesús F, SCHLAG, Rudolf, KHUAGEVA, Nuriet K, DIMOPOULOS, Meletios A, SHPILBERG, Ofer, KROPFF, Martin, SPICKA, Ivan, PETRUCCI, Maria T, PALUMBO, Antonio

“…The purpose of this study was to confirm overall survival (OS) and other clinical benefits with bortezomib, melphalan, and prednisone (VMP) versus melphalan…”
Get full text

Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180 by TREON, Steven P, LOAKIMIDIS, Leukothea, KEOGH, George P, MYERS, Thomas J, BORAL, Andy, BIRNER, Ann, ESSELTINE, Dixie L, GHOBRIAL, Irene M, SOUMERAI, Jacob D, PATTERSON, Christopher J. J, SHEEHY, Patricia, NELSON, Marybeth, WILLEN, Michael, MATOUS, Jeffrey, MATTERN, John, DIENER, Jakow G

“…We examined the activity of bortezomib, dexamethasone, and rituximab (BDR) in patients with symptomatic, untreated Waldenström macroglobulinemia (WM). A cycle…”
Get full text

Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma by Richardson, Paul G, Sonneveld, Pieter, Schuster, Michael W, Irwin, David, Stadtmauer, Edward A, Facon, Thierry, Harousseau, Jean-Luc, Ben-Yehuda, Dina, Lonial, Sagar, Goldschmidt, Hartmut, Reece, Donna, San-Miguel, Jesus F, Bladé, Joan, Boccadoro, Mario, Cavenagh, Jamie, Dalton, William S, Boral, Anthony L, Esseltine, Dixie L, Porter, Jane B, Schenkein, David, Anderson, Kenneth C

“…Bortezomib, an inhibitor of proteasomes (sites of protein degradation in cells), has activity against advanced multiple myeloma. This study compared bortezomib…”
Get full text

Bortezomib in recurrent and/or refractory multiple myeloma: Initial clinical experience in patients with impaired renal function by JAGANNATH, Sundar, BARLOGIE, Bart, ESSELTINE, Dixie L, ANDERSON, Kenneth C, BERENSON, James R, SINGHAL, Seema, ALEXANIAN, Raymond, SRKALOVIC, Gordan, ORLOWSKI, Robert Z, RICHARDSON, Paul G, ANDERSON, Jessica, NIX, Darrell

Get full text

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone by Jagannath, S, Richardson, PG, Barlogie, B, Berenson, , JR, Singhal, S, Irwin, D, Srkalovic, G, Schenkein, DP, Esseltine, DL, Anderson, KC, SUMMIT/CREST Investigators

“…St. Vincent's Comprehensive Cancer Center, 325 West 15th Street, New York, NY, USA. sjagannath@aptiumoncology.com BACKGROUND AND OBJECTIVEs: The efficacy and…”
Get full text

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma by Berenson, James R., Jagannath, Sundar, Barlogie, Bart, Siegel, David T., Alexanian, Raymond, Richardson, Paul G., Irwin, David, Alsina, Melissa, Rajkumar, S. Vincent, Srkalovic, Gordon, Singhal, Seema, Limentani, Steven, Niesvizky, Ruben, Esseltine, Dixie L., Trehu, Elizabeth, Schenkein, David P., Anderson, Kenneth

“…BACKGROUND Bortezomib, a first‐in‐class proteasome inhibitor, is active with manageable toxicities in relapsed and/or refractory myeloma. METHODS Bortezomib…”
Get full text

Bortezomib in recurrent and/or refractory multiple myeloma by Jagannath, Sundar, Barlogie, Bart, Berenson, James R., Singhal, Seema, Alexanian, Raymond, Srkalovic, Gordan, Orlowski, Robert Z., Richardson, Paul G., Anderson, Jessica, Nix, Darrell, Esseltine, Dixie L., Anderson, Kenneth C.

“…BACKGROUND Bortezomib is a potent, reversible proteasome inhibitor that has been approved for the treatment of recurrent and/or refractory multiple myeloma,…”
Get full text

The Anti-Myeloma Effect of Bortezomib Is Associated with Osteoblastic Activity by Zangari, Maurizio, Najarian, Kevin B., Esseltine, Dixie L., Lee, Choon-Kee, Barlogie, Bart, Elice, Francesca, Burns, Michael J., Yaccoby, Shmuel, Richardson, Paul, Sonneveld, Pieter

“…Myeloma bone disease is characterized by osteolytic destruction associated with suppressed osteoblastic activity possibly through inhibition of the WNT…”
Get full text

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function by Jagannath, Sundar, Barlogie, Bart, Berenson, James R, Singhal, Seema, Alexanian, Raymond, Srkalovic, Gordan, Orlowski, Robert Z, Richardson, Paul G, Anderson, Jessica, Nix, Darrell, Esseltine, Dixie L, Anderson, Kenneth C

“…Bortezomib is a potent, reversible proteasome inhibitor that has been approved for the treatment of recurrent and/or refractory multiple myeloma, but its…”
Get full text